UK Markets closed

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.8500-0.1700 (-3.39%)
At close: 04:00PM EST
4.8900 +0.04 (+0.82%)
After hours: 05:29PM EST
Sign in to post a message.
  • S
    SamiJ
    I don’t have any doubt that ACIU stock will reach $12.5 and above in the near future
  • G
    Gypsy
    ACI-35.030 and ACI-24 data presentation are yet to come this week and the data presented today is encouraging for mild to moderate AD treatment as it resulted in 43% decline in the cognition statistically.
  • M
    MrT
    THE philanthropist stock!! Cure for Alzheimer’s disease 🙏
  • K
    KP
    Looks like a "sell on the news" scenario. Which is sad. Positive results in this space usually pops a stocks up about 10%.
  • M
    MrT
    AC Immune's buy rating reiterated at SVB Leerink LLC. $17.00 PT.
    Rather modest, I think…
  • M
    MrT
    Today @ 8 am the new results for ACI-35.030 Anti-pTau Vaccine will be disclosed…
  • T
    Thanos-a-diol
    Late breaking results of today are very interesting. We may have something of a winner in the tau mAB, but the failures MIGHT be warning us that once the disease damage is done, anti tau mAB might not reverse brain damage. It MAY be that the damage is permament. Still very interesting news and a trade entry possibility once the price finds the final dip.
  • M
    MrT
    3 exciting updates November 9-12 !!

    LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announces that new data on its investigational Alzheimer’s disease (AD) candidates semorinemab, ACI-35.030 and ACI-24 will be featured in the scientific program of the Clinical Trials on Alzheimer’s Disease (C-TAD) Conference, taking place virtually and in person in Boston, on November 9-12, 2021.

    Scientific updates at CTAD 2021

    Semorinemab monoclonal anti-tau antibody
    Title: Phase 2 Trial of Semorinemab in Mild-to-Moderate Alzheimer’s Disease (Lauriet): Topline results
    Presenter: late-breaking readout roundtable by Cecilia Monteiro
    Date: Wednesday November, 10 I 10.50am-11.20am EST I In-person session streamed live in the digital platform of CTAD I Available on demand 48 hours after the session.

    ACI-35.030 Anti-pTau Vaccine
    Title: ACI-35.030, a novel anti-phospho-Tau vaccine for the treatment of Alzheimer’s Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity
    Presenter: oral presentation by Johannes Streffer
    Date: Friday, November 12 I Available on demand in the digital platform of CTAD from 08:00am EST

    ACI-24 anti-beta amyloid vaccine
    Title: ACI-24, an anti-beta amyloid vaccine, in patients with mild Alzheimer’s disease: Results of a phase 2, randomized, double-blind, placebo-controlled study
    Presenter: Poster P44 presented by Olivier Sol
    Date: November 9-12 I Available on the digital platform of CTAD at all times
  • M
    Matija
    Guys one should carefully read the results published today. This vaccine has bright future. I am adding more shares. Going long.
  • M
    MrT
    The vaccine is why the Struengman brothers (BNTX) recently invested into ACIU…Presentation tomorrow @ 8am EST could be the catalyst both in terms of content & timing as before the bell!!

    ACI-35.030 Anti-pTau Vaccine
    Title: ACI-35.030, a novel anti-phospho-Tau vaccine for the treatment of Alzheimer’s Disease: Interim Phase 1b/2a data on safety, tolerability and immunogenicity
    Presenter: oral presentation by Johannes Streffer
    Date: Friday, November 12 I Available on demand in the digital platform of CTAD from 08:00am EST
  • J
    John
    @MrT, read the latest press announcement. Andreas and Thomas Struengmann, anchor investors of BioNTech (Pfizer vaccine) along with MIG and First Capital Partner hold a 12% stake in ACIU.
  • B
    Biotechinvest Net
    I bet on tau therapy of AD but it is better to have both i.e. anti-beta-amyloid and anti-tau immunization in portfolio. SAVA, ANVS, ALZN will fail to cure AD but ACIU has very high probability to win.
    Recently published paper said that:
    "While Aβ aggregation is believed to be an important event in the development of AD, clinical symptoms, atrophy, and brain damage correlate best with the appearance of tau aggregates (4). Tau aggregates have the ability to self-replicate, and these replication-competent aggregates are referred to as proteopathic seeds. Once an initial seed is present, it can replicate to form a large number of new seeds. Synthetic tau filaments made from recombinant protein and filamentous material extracted from tau mouse models or AD brains have been shown to act as seeds in various model systems and initiate tau pathology (5–9). Furthermore, several mouse model systems provide evidence that seeds spread from the regions in which they are initially formed to other regions of the brain and trigger aggregation there"
    Read the paper ("In vivo rate-determining steps of tau seed accumulation in Alzheimer’s disease") and buy ACIU now before pps jump to $10 and higher.
    https://www.science.org/doi/10.1126/sciadv.abh1448
    Local replication doubles the number of tau aggregate in Alzheimer’s disease only once every 5 years, limiting the overall rate.
    Local replication doubles the number of tau aggregate in Alzheimer’s disease only once every 5 years, limiting the overall rate.
    www.science.org
  • S
    SamiJ
    I expect +300% up in the next three days!
  • M
    MrT
    Interview with Dr Pfeifer, CEO @ ACIU: "In fact, I think we are on the verge of a breakthrough." Andrea Pfeifer, CEO AC Immune @ Wirstchaftswoche…
    ….If the lady is right, that will be the next 5000% stock!
  • M
    MrT
    As for investors: this is a $100++ stock …
  • d
    denardi
    I heard about ACIU the other day on (http://trademarketview.tech). It’s looking like an interesting play.
  • M
    MrT
    Could not resist and bought more today…
  • D
    Dan
    Wonder if this will rocket like sava
  • M
    MrT
    News Alert!! Big news coming soon towards commercialization/acquisition/cooperation!!
    LAUSANNE, Switzerland, Oct. 29, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors. Dr. Shaw and Prof. Bütler replace Mr. Martin Velasco and Peter Bollmann, Ph.D., who stepped down from the Board following the EGM.

    Douglas Williams, Ph.D., Chairman of the Board of Directors of AC Immune, commented: "Dr. Shaw and Prof. Bütler are accomplished industry leaders with complementary skill sets and we are delighted to welcome them to the Board. Dr. Shaw's extensive executive and drug development experience, together with Prof. Bütler's deep expertise in finance and economics, will be invaluable as we work to revolutionize the diagnosis and treatment of Alzheimer's and other neurodegenerative diseases. We are eager to begin working with them and look forward to benefiting from their strategic insights. We also extend our sincere thanks to Mr. Velasco and Dr. Bollmann, as their contributions as Directors helped to establish AC Immune's position as an industry leader."

    Dr. Shaw commented: "Joining AC Immune's Board is a truly exciting opportunity. The Company is at the forefront of its field with a unique precision medicine approach that properly recognizes the complexity of neurodegenerative disease as well as the importance of earlier intervention. I look forward to working with my fellow Directors to provide valuable insights and guidance as the Company advances its industry-leading strategy."
  • S
    SamiJ
    It most take a few hours until investors remove the noise from the presentation and realize the great value of presented achievements